In a systematic review it has been proposed that PPARγ agonists probably lead to a reduction of recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (Liu and Wang, 2017). The gene discussed is PPARG; the disease is stroke disorder.